Elizabeth Berry-Kravis is professor of child neurology at Rush University Medical Center in Chicago.
Elizabeth Berry-Kravis
Professor
Rush University Medical Center
From this contributor
Analysis offers new hope for failed fragile X drug
Eye tracking shows that mavoglurant, a once-abandoned experimental drug for fragile X syndrome, enters the brain and boosts social interest, says Elizabeth Berry-Kravis.
Analysis offers new hope for failed fragile X drug
Questions for Elizabeth Berry-Kravis: Dodging mouse traps
A mouse model of fragile X syndrome lacks a key feature of the condition, prompting researchers to look for other ways to test treatments.
Questions for Elizabeth Berry-Kravis: Dodging mouse traps
Questions for Elizabeth Berry-Kravis: Measuring drug effects
Drugs designed to treat fragile X syndrome have yet to show substantial benefits in people. But rather than abandon them, child neurologist Elizabeth Berry-Kravis suggests a new way to measure their effectiveness.
Questions for Elizabeth Berry-Kravis: Measuring drug effects
Explore more from The Transmitter
Finding the Rett syndrome gene and ways to fix it
Kevin Mitchell talks with Huda Zoghbi about her work identifying the MECP2 gene, its role in the brain and therapies to address its dysfunction.
Finding the Rett syndrome gene and ways to fix it
Kevin Mitchell talks with Huda Zoghbi about her work identifying the MECP2 gene, its role in the brain and therapies to address its dysfunction.
Measuring plastic in the brain: Improving, but incomplete
Meanwhile, researchers are publishing papers without “sufficient quality control,” says analytical chemist Dušan Materić.
Measuring plastic in the brain: Improving, but incomplete
Meanwhile, researchers are publishing papers without “sufficient quality control,” says analytical chemist Dušan Materić.
Incredible shrinking grant deadlines at the BRAIN Initiative
“A month is crazy,” says one former recipient, referring to a new funding opportunity’s timeline.
Incredible shrinking grant deadlines at the BRAIN Initiative
“A month is crazy,” says one former recipient, referring to a new funding opportunity’s timeline.